{"id":"aegr-733-and-fenofibrate","safety":{"commonSideEffects":[{"rate":null,"effect":"Gastrointestinal disturbances (diarrhea, abdominal discomfort)"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Muscle-related adverse events"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AEGR-733 inhibits MTP, which is essential for the assembly and secretion of apolipoprotein B-containing lipoproteins, thereby reducing triglyceride and LDL levels. Fenofibrate acts as a PPARα agonist to further lower triglycerides and raise HDL cholesterol. The combination targets multiple pathways in lipid metabolism to achieve greater reductions in atherogenic lipoproteins.","oneSentence":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:10.821Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe hypertriglyceridemia"},{"name":"Familial chylomicronemia syndrome"}]},"trialDetails":[{"nctId":"NCT00559962","phase":"PHASE2","title":"Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2007-10","conditions":"Hyperlipidemia","enrollment":260},{"nctId":"NCT00359281","phase":"PHASE2","title":"Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents","status":"COMPLETED","sponsor":"Aegerion Pharmaceuticals, Inc.","startDate":"2006-03","conditions":"Healthy","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AEGR-733 and fenofibrate","genericName":"AEGR-733 and fenofibrate","companyName":"Aegerion Pharmaceuticals, Inc.","companyId":"aegerion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEGR-733 is a microsomal triglyceride transfer protein (MTP) inhibitor combined with fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist, to reduce triglycerides and apolipoprotein B-containing lipoproteins. Used for Severe hypertriglyceridemia, Familial chylomicronemia syndrome.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}